We're on a mission to revolutionize mental healthcare.

Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients.

Capital

Approximately C$90M raised to date. Well-funded to progress clinical trials and M&A strategy.

Commenced trading on NEO EXCHANGE and MJDS eligible for US listing.

Canada’s largest go-public financing round in the psychedelic sector by raising C$45M. Strategic shareholder base of round subscribed to by top US biotech funds e.g., Janus Henderson, LifeSci Ventures and RA Capital.

Team

Deep Experience in healthcare, M&A, and capital markets.
CEO with over 30 years in the healthcare sector and has raised over US$4B in capital and has led over US$5B in M&A activity.

Successfully helped develop widely-used drugs: Allegra, Sabril, Anzemet & Vaniqa.

300 combined peer-reviewed publications by scientific leadership include work in addiction and psychedelics.

Overseen 60+ IND programs with FDA.

Programs

Acquired Boston-based pharmaceutical company ADELIA THERAPEUTICS INC.

Inked technology partnership with KERNEL to leverage breakthrough neuroimaging in upcoming clinical trials.

Patents

10 Patent Filings cover:
Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.

01

Novel Drug Discovery Platform

API Modification

Develop new APIs via selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharmacokinetics without modifying their therapeutic potential.

Modifications involve replacing selective hydrogens with deuterium atoms.

Optimizing unique physicochemical attributes e.g. salts, crystal forms, co-crystals, etc.

02

Proprietary Drug Delivery Systems

Research and Develop

Efficient delivery system that attempts to bypass the liver metabolism with a direct path to the brain providing a faster onset.

Modified-release formulations with the potential to reduce side effects and to control exposure.

Dose control through proprietary device platform.

Delivery systems may be applied to many psychedelic compounds.

03

Innovative Treatment Regimen

Science Meets Technology

Software-based platform to gather clinical research data from psychedelic treatment.

Machine learning-based data analytics for improved patient outcomes.

Patient therapy and integration support.

120$ / month

This plan is suitable for the beginner IT specialist and will allow you to familiarize yourself with all the main functions of the service.

1GB Storage
Mobile Version
5 Credit Reports
24/7 Support
100 Account Downloads
100 Account Downloads
3 custom Domains
All New Updates & Features

This plan is suitable for the freelancers and will allow you to familiarize yourself with all the main functions of the service.

Experience

Our relentless pursuit to commercialize these revolutionary treatments is supported by our diverse team of scientific and business experts. Our group brings the following expertise:

Experienced CEO with over 30 years in the healthcare sector, raised over US$4B in capital and has led over US$5B in M&A activity.

300 combined peer-reviewed publications by scientific leadership including work in addiction and psychedelics.

Overseen 60+ investigational New Drug Programs with the Food and Drug Administration.

The only scientific team to have successfully commercialized a psychedelic drug to date.

Supported the successful commercialization of widely-used drugs including: Allegra, Sabril, Anzement & Vaniqa with sales over $2B.

Development Pipeline

13 patent filings covering: Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.

Cybin is leveraging parent molecules that have shown positive early efficacy and optimizing their pharmacokinetics, bioavailability, and delivery through our proprietary deuterated process thus creating patent-protected, commercially scalable drug candidates.

see our programs

Partnerships

ADELIA THERAPEUTICS INC.
Acquired and successfully integrated Boston-based pharmaceutical company bringing immense experience in the scientific and psychedelic sectors.

KERNEL
Partnered with technology leader to leverage breakthrough neuroimaging hardware and software in upcoming clinical trials.

GREENBROOK TMS
Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers Of Excellence

UNIVERSITY OF WASHINGTON
Cybin Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psycotherapy

see partnerships

Our Strategy

We take a comprehensive approach to mental wellness.

Learn more about the details behind our three areas of research and development.

01

Novel Drug Discovery Platform

02

Proprietary Drug Delivery Systems

03

Innovative Treatment Regimens

learn more

Our Team

Bringing together science and business to revolutionize mental healthcare.

Doug Drysdale
CEO of Cybin

“We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients."

  • Our Company
  • Experience
  • Development Pipeline
  • Partnerships
  • Our Strategy
  • Our Team
  • Our Company
  • Experience
  • Development Pipeline
  • Partnerships
  • Our Strategy
  • Our Team
  • Our Company
  • Experience
  • Development Pipeline
  • Partnerships
  • Our Strategy
  • Our Team
  • Our Company
  • Experience
  • Development Pipeline
  • Partnerships
  • Our Strategy
  • Our Team
  • Our Company
  • Experience
  • Development Pipeline
  • Partnerships
  • Our Strategy
  • Our Team

Our Company

Experience

Our relentless pursuit to commercialize these revolutionary treatments is supported by our diverse team of scientific and business experts. Our group brings the following expertise:

  • Experienced CEO brings over 30 years in the healthcare sector, raised over US$4B in capital and has led over US$5B in M&A activity.
  • The only scientific team to have successfully commercialized a psychedelic drug to date.
  • Supported the successful commercialization of widely-used drugs: Allegra, Sabril, Anzement & Vaniqa with sales over $2B.
  • 300 combined peer-reviewed publications by scientific leadership including work in addiction and psychedelics.
  • Overseen 60+ Investigational New Drug Programs with the Food and Drug Administration.

Development Pipeline

*Partnershipdevelopment program with Catalent (NYSE:CTLT). Cybin will leverage the Zydistechnology which is regarded as one of the world’s best performing ODTs thatwould allow pre-gastric delivery and prevent first pass metabolism thus potentially improving thepharmacokinetic profile of the drug.

13 patent filings covering: Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.

Cybin is leveraging parent molecules that have shown positive early efficacy and optimizing their pharmacokinetics, bioavailability, and delivery through our proprietary deuterated process thus creating patent-protected, commercially scalable drug candidates.

  • Novel Second-Generation Psychedelics based on well-known scaffolds including Psilocybin, DMT, and MDMA with improved bioavailability.
  • 4 active drug programs targeting Major Depressive Disorder (CYB001), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Therapy Resistant Psychiatric Disorders (CYB005).
  • 50+ pre-clinical studies completed and progressing lead programs toward FDA IND filings
  • Leveraging cutting-edge Neuroimaging technology to generate quantitative data to better understand psychedelic therapies.
see our programs

Partnerships

    Adelia Therapeutics Inc.

    Acquired and successfully integrated Boston-based pharmaceutical company bringing immense experience in the scientific and psychedelic sectors.

    Kernel

    Partnered with technology leader to leverage breakthrough neuroimaging hardware and software in upcoming clinical trials.

    Greenbrook Tms

    Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of Excellence

    University of washington

    Cybin Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

    see partnerships

    We take a comprehensive approach to mental wellness.

    Learn more about the details behind our three areas of research and development.

    Our strategy

    01

    Novel Drug Discovery Platform

    02

    Proprietary Drug Delivery Systems

    03

    Innovative Treatment Regimens

    learn more

    Our team

    Bringing together science and business to revolutionize mental healthcare.

    Doug Drysdale
    CEO of Cybin

    “We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients."

    Advancing psychedelic therapeutic development to revolutionize mental healthcare.

    Learn more

    Investors

    For more information about how Cybin is leading work in the psychedelic sector, download our investor deck.
    INVESTOR DECK ↓
    in the press

    Careers at Cybin

    join our team
    press releases
    Press Release
    7.28.2021

    Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

    Read more >
    Press Release
    7.28.2021

    Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

    Read more >
    Press Release
    7.27.2021

    Cybin Announces Overnight Marketed Public Offering of Common Shares

    Read more >
    close

    Our site uses cookies. Learn more about our privacy policy.

    I accept the use of cookies